The University of Colorado Cancer Center is pleased to welcome the following new members!

Clay Smith, MDClayton Smith, MD, Full Member, Molecular Oncology

Professor, Department of Hematology/BMT, CU SOM

  • Primary Research Interests: Hematology/BMT
  • Recent publication: “An acute negative bystander effect of y-irradiated recipients on transplanted hematopoetic stem cells” (Blood, 2012)
  • Education: Fellowships, Memorial Sloan Kettering and Stanford University; MD, Southwestern Medical School, Dallas, TX; BA, Rice University

 

 

Cindy O'Bryant, PharmD

Cindy L O’Bryant, PharmD, Full Member, Developmental Therapeutics

Associate Professor, Clinical Oncology, CU SOM

  • Primary Research Interests: Developmental Therapeutics, GI Cancer
  • Recent publication: “An open label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function” (Cancer Chemother Pharmacol, 2011)
  • Education: PharmD, Mercer University Southern School of Pharmacy; BS, University of Tennessee, Knoxville

 

Xiang.WangXiang Wang, PhD, Full Member, Developmental Therapeutics

Assistant professor, Department of Organic Chemistry, CU Boulder

  • Primary Research Interests: Unspecified
  • Recent publication: “A one-pot three-component reaction for the preparation of highly functionalized tryptamines” (Tetrahedron, 2012)
  • Education: Postdoc, Harvard University; PhD, Boston University; BS, University of Science and Technology of China, Hefei.

 

John Arcaroli, PhD, Associate Member, Developmental Therapeutics

Assistant professor, Medical Oncology, CU SOM

  • Primary Research Interests: GI Cancer
  • Recent publication: “Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of caracatin oral Src inhibitor, in previously treated pancreatic cancer” (Cancer Medicine, 2012)
  • Education: PhD, University of Colorado Health Sciences Center; MS, University of Nebraska Medical Center; BS, University of Nebraska-Lincoln.

 

Melanie Joy, PhD, PharmD, Associate Member, Developmental Therapeutics

Assistant professor, Skaggs School of Pharmacy and Pharmaceutical Sciences

  • Primary Research Interests: Kidney Toxicity
  • Recent publication: “Cyclophosphamide and 4-Hydroxyxyclophosphamide pharmokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis” (Br J Clin Pharmacol)
  • Education: PhD, University of North Carolina, Chapel Hill; PharmD, Duquesne University; BS, University of Pittsburgh

 

Hong Wang, MD, PhD, Associate Member, Hormone Related Malignancies

Research Instructor, Department of Surgery, CU SOM

  • Primary Research Interests: Bladder and Prostate Cancers
  • Recent publication: “Translation initiation factor elF3b expression in human cancer and its role in tumor growth and lung colonization” (Clin Cancer Res., 2012)
  • Education: PhD, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan; MS, West China College of Medicine; MD, West China College of Medicine

 

Katja Vassiliades- Kiseljak, D.O., Associate Member, Endocrinology, Metabolism and Diabetes

Instructor, CU SOM

  • Primary Research Interests: Endocrine Neoplasms
  • Recent publication: “Reprimo (RPRM) is a novel tumor suppressor ain pituitary gland tumors and regulates survival, proliferation and tumorigenicy” (Endocrinology, 2011)
  • Education: Residency, Johns Hopkins University; DO, Midwestern University; BA Bethany College

 

James Daniel Orth, PhD, Associate Member, Cancer Cell Biology
Assistant Research Professor, MCDB, CU Boulder

  • Primary Research Interests: Developmental Therapeutics, GI Cancer, Sarcomas
  • Recent publication: “Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction” (Mol Biol Cell, 2012)
  • Education: Postdoc, Harvard University; PhD, Mayo Clinic College of Medicine; BS, University of Wisconsin, Eau Claire

 

Rebecca Oberley-Deegan, PhD, Associate Member, Cancer Cell Biology

Assistant professor, Pulmonary Medicine, National Jewish Health

  • Primary Research Interests: Prostate Cancer, Radiation Oncology
  • Recent publication: “The antioxidant, Mn TE-2-PyP, prevents side-effects incurred by prostate cancer irradiation” (PLoS ONE, 2012)
  • Education: PhD, University of Iowa; BA Grinnell College

Barish H Edil, MD, Associate Member, Developmental Therapeutics

Associate Professor, Surgical Oncology, CU SOM

  • Primary Research Interests: GI Cancer
  • Recent publication: “Serotonin expression in pancreatic neuroendocrine tumors correlates with a trabecular histologic pattern and large duct involvement (Human Pathology, 2012)
  • Education: MD, University of Wisconsin School of Medicine; BS, University of Wisconsin

 

Miriam Post, MD, Associate Member, Hormone Related Malignancies

Assistant professor, Pathology, CU SOM

  • Primary Research Interests: Breast Cancer, GYN Oncology, Hereditary Cancer
  • Recent publication: “Cutaneous decidualized endometriosis in a non-pregnant female: a potential pseudomalignancy” (Am J Dermopathology, 2012)
  • Education: Fellowship, Mass General; MD, Jefferson Medical College; BA Cornell University

 

Daniel Bowles, MD, Associate Member, Lung/Head and Neck Cancer

Assistant professor, Medical Oncology, Denver VA Medical Center

  • Primary Research Interests: Developmental Therapeutics, Head and Neck Cancer
  • Recent publication: “Vismodegin in basal cell carcinoma” (Drugs Today, 2012)
  • Education: MD, University of Colorado SOM; BA, Kenyon College